AJP - Lung Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 291: L523-L534, 2006. First published April 14, 2006; doi:10.1152/ajplung.00013.2006
1040-0605/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/L523    most recent
00013.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gosens, R.
Right arrow Articles by Halayko, A. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gosens, R.
Right arrow Articles by Halayko, A. J

Role of caveolin-1 in p42/p44 MAP kinase activation and proliferation of human airway smooth muscle

Reinoud Gosens,1,2,3 Gerald L. Stelmack,1,2 Gordon Dueck,1,2 Karol D. McNeill,1,2 Akira Yamasaki,1,2,6 William T. Gerthoffer,4 Helmut Unruh,5 Abdelilah Soussi Gounni,6 Johan Zaagsma,3 and Andrew J Halayko1,2

1Departments of Physiology and Internal Medicine, University of Manitoba, Winnipeg, Manitoba; 2Biology of Breathing Group, Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada; 3Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands; 4Department of Pharmacology, University of Nevada School of Medicine, Reno, Nevada; and 5Section of Thoracic Surgery, and 6Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada

Submitted 10 January 2006 ; accepted in final form 13 April 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Chronic airways diseases, including asthma, are associated with an increased airway smooth muscle (ASM) mass, which may contribute to chronic airway hyperresponsiveness. Increased muscle mass is due, in part, to increased ASM proliferation, although the precise molecular mechanisms for this response are not completely clear. Caveolae, which are abundant in smooth muscle cells, are membrane microdomains where receptors and signaling effectors can be sequestered. We hypothesized that caveolae and caveolin-1 play an important regulatory role in ASM proliferation. Therefore, we investigated their role in p42/p44 MAPK signaling and proliferation using human ASM cell lines. Disruption of caveolae using methyl-beta-cyclodextrin and small interfering (si)RNA-knockdown of caveolin-1 caused spontaneous p42/p44 MAPK activation; additionally, caveolin-1 siRNA induced ASM proliferation in mitogen deficient conditions, suggesting a key role for caveolae and caveolin-1 in maintaining quiescence. Moreover, caveolin-1 accumulates twofold in myocytes induced to a contractile phenotype compared with proliferating ASM cells. Caveolin-1 siRNA failed to increase PDGF-induced p42/p44 MAPK activation and cell proliferation, however, indicating that PDGF stimulation actively reversed the antimitogenic control by caveolin-1. Notably, the PDGF induced loss of antimitogenic control by caveolin-1 coincided with a marked increase in caveolin-1 phosphorylation. Furthermore, the strong association of PDGF receptor-beta with caveolin-1 that exists in quiescent cells was rapidly and markedly reduced with agonist addition. This suggests a dynamic relationship in which mitogen stimulation actively reverses caveolin-1 suppression of p42/p44 MAPK signal transduction. As such, caveolae and caveolin-1 coordinate PDGF receptor signaling, leading to myocyte proliferation, and inhibit constitutive activity of p42/p44 MAPK to sustain cell quiescence.

airway remodeling; hyperplasia; airway smooth muscle phenotype; platelet-derived growth factor receptor-beta; asthma

CAVEOLAE ARE FLASK-SHAPED invaginations of the cell membrane that are abundant in numerous cell types, including endothelial and epithelial cells, type I pneumocytes, striated and smooth muscle cells, and adipocytes. Typically 50–100 nm in size, caveolae are macroscopically distinct from much larger clathrin-coated pits. Caveolae are also biochemically distinct, because they are cholesterol and sphingolipid enriched, and they contain high amounts of caveolin proteins. Three caveolins, caveolin-1, -2, and -3, which are derived from distinct genes, have been identified. Caveolins serve a structural role, inducing and maintaining caveolae invaginations, and can act as scaffold proteins to sequester and modulate the activity of numerous signaling effector and receptor proteins (6).

In airway smooth muscle, the primary caveolae protein expressed is caveolin-1 (6). In these cells, caveolae are abundant and frequently located in proximity to intracellular sarcoplasmic reticulum (27). This suggests a role in the regulation of airway smooth muscle contractile responses, which is supported by reports that caveolae are enriched in a number of proteins involved in Ca2+ handling (8). An additional role for caveolae and caveolin-1 in regulating vascular and bladder smooth muscle proliferation has been reported (39, 47). Growth factor-induced vascular myocyte proliferation is associated with reduced expression of caveolin-1, whereas overexpression of caveolin-1 attenuates vascular myocyte growth (39). To date, no studies have examined the functional role of caveolins in airway smooth muscle cell proliferation.

There appears to be a clear association between caveolae, and growth factor receptors and their signaling effectors; however, the precise role of caveolins as determinants of cell responses to mitogens is not entirely clear. Proteomic studies of HeLa cells demonstrate the association of both receptor and nonreceptor tyrosine kinases with lipid rafts and caveolae (9). Furthermore, platelet-derived growth factor (PDGF) receptor-mediated activation of p42/p44 mitogen-activated protein (MAP) kinase signaling in normal human fibroblasts is localized to caveolae (29, 30). Similarly, PDGF-induced mitogenic signaling in human bladder smooth muscle cells requires intact caveolae, because their disruption by cholesterol-depleting agents inhibits mitogen induced DNA synthesis (47). In contrast to such a supportive role in cell proliferation, a number of reports indicate that caveolins can inhibit PDGF receptor activation through binding of the receptor to a conserved caveolin scaffolding domain (53). Similarly, caveolin-1 overexpression inhibits cell cycle progression in NIH3T3 fibroblasts (12) and reduces PDGF-induced proliferation of vascular smooth muscle cells (39). Collectively, these studies suggest an important role for caveolae and caveolin-1 in regulating growth factor-induced signaling and proliferation. However, the mechanisms involved that might explain their apparent dual pro- and antimitogenic role are not understood.

Signaling mechanisms that are involved in airway smooth muscle proliferation are important, because increased airway smooth muscle mass due, in large part, to increased myocyte number, is commonly observed in patients suffering from chronic airways diseases, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis (21, 23, 51). Therefore, we studied the role of caveolae and caveolin-1 in constitutive and PDGF-induced p42/p44 MAP kinase signaling and airway smooth muscle proliferation. We found evidence for a dynamic role for caveolae and caveolin-1 by inhibiting constitutive activation of p42/p44 MAP kinase and cell proliferation, which was actively reversed in the presence of PDGF. These results indicate that caveolae and caveolin-1 play an important role in maintaining airway smooth muscle cell quiescence, and provide novel insights concerning possible mechanisms underlying the role for caveolin-1 in orchestrating and modulating growth factor receptor-associated signaling.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell culture. Three human bronchial smooth muscle cell lines, immortalized by stable expression of human telomerase reverse transcriptase (hTERT), were used for all experiments. Expression of hTERT extends the life span of endothelial cells, fibroblasts, and smooth muscle cells (3, 7, 32, 54). The primary cultured human bronchial smooth muscle cells used to generate each cell line were prepared as our laboratory has previously described (35, 41) from macroscopically healthy segments of second- to fourth-generation main bronchus obtained after lung resection surgery from patients with a diagnosis of adenocarcinoma. All procedures were approved by the Human Research Ethics Board (University of Manitoba).

To extend the life span of cultured human airway smooth muscle cells we infected primary and low-passage cultures with a retrovirus vector encoding the hTERT gene. A plasmid (pGRN145) containing hTERT cDNA expression vector was a gift of the Geron (Menlo Park, CA). The hTERT expression cassette was cloned into pLXIN (Clontech), and replication-incompetent Moloney murine leukemia virus retrovirus was generated in HEK293 retroviral packaging cells. Primary and first-passage cultures of human airway smooth muscle cells were infected with the hTERT retrovirus and selected with 100 mg/ml G418 for 1 wk. Expression of hTERT was verified in immortalized cells by RT-PCR using telomerase-specific primers. Immortalized cells were passaged (4:1 dilution) up to 60 times with no evidence of senescence (13). For all experiments, passages 10–16 myocytes grown on uncoated plastic dishes in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 50 U/ml streptomycin, 50 µg/ml penicillin, and 10% fetal bovine serum were used. Unless otherwise specified, cells were grown to a subconfluent (~70%) condition and serum starved for 3 days in DMEM supplemented with 50 U/ml streptomycin, 50 µg/ml penicillin, 5 µg/ml insulin, 5 µg/ml transferrin, and 5 ng/ml selenium before each experiment.

Immunocytochemistry. Cells were seeded onto precleaned, uncoated glass coverslips in culture dishes. Cells were grown to confluence and then maintained in serum-free medium for 7 days. Cells were then fixed, permeabilized, and immunolabeled using anti-caveolin-1, anti-calponin, or anti-vimentin. FITC- or Cy3-conjugated secondary antibodies were used to detect primary antibody bound to labeled cells. Nuclei were labeled with Hoechst 33342 (10 µg/ml). Coverslips were mounted using antifade medium and digitally imaged as described previously (19).

Preparation of cell lysates. Cells were subjected to different treatments in DMEM. To extract cellular cholesterol and disrupt caveolae, cell monolayers were pretreated (60 min, 37°C) with 5 mM methyl-beta-cyclodextrin, followed by two washes in DMEM, before stimulation with PDGF. To obtain total cell lysates, cells were washed once with ice-cold phosphate-buffered saline (PBS) then lysed in ice-cold RIPA buffer (composition: 40 mM Tris, 150 mM NaCl, 1% Igepal CA-630, 1% deoxycholic acid, 1 mM NaF, 1 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 7 µg/ml pepstatin A, 1 mM PMSF, pH 8.0). Lysates were stored at –80 °C until further use.

Western analysis. Equal amounts of protein were subjected to electrophoresis, transferred to nitrocellulose membranes, and analyzed for the proteins of interest using specific primary and horseradish peroxidase (HRP) -conjugated secondary antibodies. Bands were subsequently visualized on film using enhanced chemiluminescence reagents.

Isolation of caveolae membrane fractions. Cells grown on uncoated 150 mm dishes were washed with ice-cold PBS, and lysed in 500 mM sodium carbonate (pH 11.0) supplemented with 1 mM Na3VO4, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 7 µg/ml pepstatin A, and 1 mM PMSF. After homogenization by passing the cells through a 20-gauge needle 10 times, 2 ml of homogenate was mixed with an equal volume of a solution containing 150 mM NaCl, 25 mM MES and 80% (wt/vol) sucrose, pH 6.5, and placed in the bottom of a centrifuge tube. A stepwise sucrose density gradient (30%, 20%, and 5%) was then carefully layered on top of the homogenate. Thereafter, the samples were centrifuged at 210,000 g for 18 h, and 1-ml fractions were then collected from the top of the gradient. Samples were stored at –80°C until further use.

siRNA transfection. Cells were grown to 50–70% confluence and transiently transfected with a 21-bp, double-stranded small-interfering (si)RNA targeted against a sequence between residues 529 and 589 of the caveolin-1 transcript (cat. code 1022605, Qiagen, Mississauga, Ontario, Canada). Cells in 35-mm-diameter plates were transfected using 2.5 µg/ml of siRNA in combination with 6 µl/µg siRNA of RNAiFect transfection reagent (Qiagen). In all studies, control transfections were performed using a nonsilencing control 21-bp siRNA (cat. code 1022076, Qiagen). After 72 h, cells were washed with fresh DMEM and used for experiments, because caveolin-1 knockdown was maximal at this time point (temporal data not shown). Transfection efficiency was monitored by transfecting cells with a FITC-conjugated nonsilencing control siRNA (Qiagen). Four hours after transfection in serum-free DMEM, cells were washed three times with sterile Hanks’ balanced salt solution (HBSS). Labeled cells were digitally visualized using an Olympus Fluoview confocal microscope (Olympus America, Melville, NY).

Proliferation assay. Cells were grown to 50–70% confluence in 24-well cluster plates, and then they were serum starved for 3 days in DMEM supplemented with 5 µg/ml insulin, 5 µg/ml transferrin, and 5 ng/ml selenium. In some experiments, cells were transfected with siRNA during this 3-day period. Cells were then incubated with mitogens for 4 days in DMEM supplemented with 50 U/ml streptomycin and 50 µg/ml penicillin. Thereafter, cells were washed two times with HBSS and incubated with HBSS containing 10% vol/vol Alamar blue solution (Biosource, Camarillo, CA). Conversion of Alamar blue into its reduced form by mitochondrial cytochromes was then assayed by dual wavelength spectrophotometry at wavelengths of 562 and 630 nm. As indicated by the manufacturer, the degree of Alamar blue conversion is proportional to cell number; this was confirmed by our preliminary experiments using our human airway myocyte cultures (see Fig. 5A).


Figure 5
View larger version (15K):
[in this window]
[in a new window]
  		Fig. 5. Effects of siRNA knockdown of caveolin-1 on basal and PDGF-induced human airway myocyte proliferation. A: comparison of the Alamar blue proliferation assay to manual cell counts as a method to estimate changes in cell number in response to PDGF-BB (30 ng/ml) for 4 days. Values are normalized as %increase in estimated cell number of cultures maintained for 4 days in growth factor-deficient conditions. **P ≤ 0.01 compared with cultures maintained in growth factor-deficient conditions. B: proliferation of hTERT human airway smooth muscle cell lines, estimated using Alamar blue assay, in response to increasing concentrations of PDGF-BB for 4 days. Values are normalized as %increase in estimated cell number of cultures maintained for 4 days in growth factor-deficient conditions. Results shown are means ± SE obtained from 3 triplicate experiments using 3 different cell lines. ***P ≤ 0.001. C and D: effects of siRNA knockdown of caveolin-1 on proliferation of myocytes maintained in growth factor- and serum-deficient culture media (basal) or stimulated with PDGF. Cells were transfected either with control nonsilencing siRNA or siRNA directed against caveolin-1. For PDGF stimulation, 3 days after transfection cells were stimulated with 30 ng/ml PDGF-BB for 4 days. Cell proliferation was assayed 3 days after transfection (before PDGF stimulation; C) and 7 days after transfection (after 4 days of PDGF stimulation; D). Estimates of cell number are all normalized to that determined for myocytes transfected with nonsilencing siRNA maintained in growth factor-deficient conditions. Results shown are means ± SE obtained from 6 experiments. *P < 0.05. NS, not significant. E: effect of the MEK inhibitor U-0126 (+U-0126; 3 µM), applied during transfection and thereafter, on caveolin-1 siRNA-induced cell proliferation. Estimates of cell number are all normalized to that determined for myocytes transfected with nonsilencing siRNA maintained in the absence of U-0126. Results shown are means ± SE obtained from 3 experiments performed in duplicate. *P ≤ 0.05.

 
Immunoprecipitation. Anti-caveolin-1 was conjugated to protein-A Sepharose beads immediately before use by incubating (1 h, 4°C) 30 µl of a 50% Sepharose slurry with polyclonal rabbit anti-caveolin-1 IgG (200 µg/ml), diluted 1:100 in 0.5 ml PBS, directed against the NH2-terminal sequence of caveolin-1 (Santa Cruz Biotechnology, Santa Cruz, CA). Beads were then washed three times with RIPA buffer, blocked with 10% BSA, and transferred to 500 µg of cell lysate. After 1-h incubation at 4°C, beads were washed four times with extraction buffer and once with PBS. Beads with immunoprecipitated proteins were then stored at –80°C until used for Western analysis.

Antibodies and reagents. Platelet-derived growth factor-BB was purchased from Calbiochem (La Jolla, CA). Mouse anti-smooth muscle (sm)-{alpha}-actin monoclonal antibody, mouse anti-beta-actin monoclonal antibody, mouse monoclonal anti-sm-myosin heavy chain (MHC) antibody, mouse anti-calponin monoclonal antibody, mouse anti-vimentin monoclonal antibody, mouse anti-desmin monoclonal antibody, HRP-conjugated goat anti-mouse antibody, and HRP-conjugated goat anti-rabbit antibody were purchased from Sigma (St. Louis, MO). FITC- and Cy3-conjugated secondary antibodies were obtained from Jackson ImmunoResearch (West Grove, PA). Mouse anti-caveolin-1 monoclonal antibody and mouse anti-Tyr14 phosphorylated caveolin-1 monoclonal antibody were obtained from BD Biosciences (San Jose, CA). Rabbit anti-caveolin-1 polyclonal antibody and rabbit anti-clathrin heavy chain polyclonal antibody were purchased from Santa Cruz Biotechnology. U-0126, rabbit anti-PDGF receptor-beta (PDGFR-beta) polyclonal antibody, mouse anti-phospho-Thr202/Tyr204-p42/p44 MAPK monoclonal antibody, and rabbit anti-p42/p44 MAPK polyclonal antibody were all from Cell Signaling Technology (Beverly, MA). All other chemicals were of analytical grade.

Data analysis. Values reported for all data represent means ± SE. For all studies, replicate data from three different cell lines were obtained. The statistical significance of differences between means was determined by an unpaired two-tailed Student’s t-test. Differences were considered to be statistically significant when P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Phenotypic characterization of the hTERT-immortalized bronchial smooth muscle cell lines. Each cell line was thoroughly characterized to passage 10 and higher for expression of a number of sm mature phenotype marker proteins (e.g., sm-MHC, sm-{alpha}-actin, desmin, and calponin). Each cell line retained capacity for abundant expression of each marker protein even at high passage number (Fig. 1). Furthermore, in a manner similar to primary human airway smooth muscle cells (18), spontaneous marker protein expression was markedly induced during prolonged serum deprivation (Fig. 1E). Collectively, these observations demonstrate that the hTERT-immortalized bronchial smooth muscle cell lines retain fundamental phenotypic properties of low-passage-number primary cultured human airway smooth muscle cells.


Figure 1
View larger version (61K):
[in this window]
[in a new window]
  		Fig. 1. Phenotypic characterization of human telomerase reverse transcriptase (hTERT)-immortalized human bronchial smooth muscle cell lines. A: phase contrast microscopy showing a typical hTERT cell line. Individual cells exhibit a spindle-shape and are ordered into parallel "bundles" coursing through the culture dish in a manner typical of low-passage primary cells. Fluorescent immunocytochemistry of hTERT cells after 7-day serum deprivation (B, C, and D) demonstrates the abundant expression of mature phenotype markers calponin (B) and vimentin (C) and of caveolin-1 (D). Nuclei are stained with Hoechst 33342 (blue). E: Western analysis of cell lysates reveals abundant expression of smooth muscle specific phenotypic marker proteins, including smooth muscle myosin heavy chain (sm-MHC), sm-{alpha}-actin, desmin, and calponin. Marker protein expression by hTERT immortalized human bronchial smooth muscle cell lines was markedly increased by prolonged (7 days) serum deprivation. SF, serum-fed, subconfluent cultures; SD, 7-day serum-deprived, confluent cultures. Results shown are typical of all cell lines used in this study.

 
Subcellular localization of PDGFR-beta. Receptor tyrosine kinases, including PDGF receptors, appear to localize to caveolae, based on observations that these proteins cosegregate with caveolin-1 in caveolae-isolation experiments (9, 29, 53). In these protocols, caveolae are separated, based on their low buoyant density and insolubility in carbonate buffer (pH 11.0) or in buffers containing Triton X-100 at 4°C (40). In our experiments using the carbonate method, caveolae were primarily detected as an opaic band near the interface of the 5 and 20% sucrose layers. Because PDGFR-beta is the primary PDGF receptor expressed in airway smooth muscle (22), we assessed its subcellular distribution and found that it cosegregated with caveolae, and it was virtually absent from other cellular compartments (Fig. 2). Densitometric analysis demonstrated that 95 ± 2% (n = 3) of total PDGFR-beta was in the low-buoyant-density fractions (Fig. 2C).


Figure 2
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 2. Platelet-derived growth factor receptor-beta (PDGFR-beta) associates with caveolae microdomains on human airway myocytes. Cells were grown to subconfluence and serum deprived 3 days before homogenization in carbonate buffer for caveolae isolation using sucrose density gradient centrifugation. After centrifugation, 1-ml fractions were collected from the top (i.e., buoyant density increases with increasing fraction number). Equal amounts of protein (A) or equal volumes (B) from each fraction were subjected to Western analysis for the indicated proteins. Results shown are representative for all cell lines used in this study. C: densitometric data for comparison of caveolin-1 and PDGFR-beta subcellular protein distribution, based on equal volume loading. Results shown are means ± SE obtained from 3 experiments. MAPK, p42/p44 mitogen-activated protein kinase.

 
Although we occasionally detected p42/p44 MAP kinase in caveolin-1-containing fractions, the majority of the enzyme was evident in the soluble cellular fractions that remain in the bottom of the sucrose gradient. Of note, clathrin heavy chain appeared exclusively in the bottom fractions, indicating that clathrin-coated pits had been effectively solubilized by the carbonate buffer and had not contaminated the caveolin-rich membrane fractions. Some reports suggest that caveolae isolation using carbonate and Triton X-100 protocols can produce contrary results (9, 40); therefore, in a parallel study we used the latter method, and found the relative subcellular distribution of caveolin-1, PDGFR-beta, and p42/p44 MAP kinase to be the same as that we observed using carbonate buffer extraction (data not shown). Collectively, the data obtained using our cell fractionation protocols reveal an association of PDGFR-beta but not p42/p44 MAP kinase with caveolin-1 membrane fractions in unstimulated human airway smooth muscle cells.

Role of caveolae and caveolin-1 in p42/p44 MAP kinase activation. We next tested whether the association of PDGFR-beta with caveolae was of functional significance. We used methyl-beta-cyclodextrin (5 mM) to extract cholesterol. The concentration of methyl-beta-cyclodextrin we used is known to effectively disrupt cholesterol-enriched membrane microdomains including caveolae (16, 26). Interestingly, methyl-beta-cyclodextrin treatment significantly activated p42/p44 MAP kinase, because after treatment, basal levels of phospho-p42/p44 MAP kinase were significantly increased in the absence of any change in total p42/p44 MAP kinase content. Subsequent PDGF-BB exposure failed to further increase p42/p44 MAP kinase activation (Fig. 3), whereas PDGF-BB exposure on control cells induced a significant concentration-dependent phosphorylation of p42/p44 MAP kinase with maximum induction observed using 30 ng/ml PDGF-BB for 5 min (Fig. 3).


Figure 3
View larger version (26K):
[in this window]
[in a new window]
  		Fig. 3. Effects of methyl-beta-cyclodextrin treatment on basal and platelet-derived growth factor (PDGF)-induced p42/p44 mitogen-activated protein (MAP) kinase activation. Cell monolayers were pretreated (60 min, 37°C) with 5 mM methyl-beta-cyclodextrin (MbetaCD) to extract cellular cholesterol and subsequently were stimulated with increasing concentrations of PDGF-BB (from 0 to 30 ng/ml) for 5 min. After repeated washouts of the methyl-beta-cyclodextrin-treated and control plates, protein lysates were prepared in the presence of protease and phosphatase inhibitors. A: equal amounts of protein were then subjected to Western blotting and densitometry for analysis of phosphorylated (phospho) and total p42/p44 MAP kinase abundance. A representative set of blots are shown. B: densitometric data for comparison of phospho-p42/p44 MAP kinase. Data from each experiment were normalized to maximal (30 ng/ml, 5 min) PDGF-BB-induced levels of phospho-p42/p44 MAP kinase in control cultures. Results shown are means ± SE obtained from 6 experiments. Brackets denote concentration. **P < 0.01.

 
The specificity of methyl-beta-cyclodextrin for caveolae microdomains is somewhat limited, because treatment disrupts all cholesterol-enriched lipid rafts. Moreover, it is known that the dual-specific phosphatase complex involved in p42/p44 MAP kinase dephosphorylation is cholesterol dependent, and it can be disassembled by cyclodextrins (50). This could contribute to the apparently maximal p42/p44 MAP kinase activation by methyl-beta-cyclodextrin and mask further inducibility by PDGF-BB. Therefore, in additional studies we used siRNA directed against caveolin-1 as a far more specific approach to investigate the functional role of caveolin-1 protein in PDGF induced signaling and cell proliferation. Our preliminary experiments showed that caveolin-1 knockdown was maximal 3 days after transient transfection with siRNA. On average, caveolin-1 protein abundance was reduced to 55 ± 3% (Fig. 4, B and C; P < 0.001), whereas the abundance of total p42/p44 MAP kinase (102 ± 20%), beta-actin (101 ± 6%), and PDGFR-beta (87 ± 16%) were not affected (Fig. 4, B and C). Caveolin-1 knockdown was very likely homogeneous in cells because caveolin-1 is more or less the same for individual cells (Fig. 1D), and transfection efficiency was ≥ 95% (Fig. 4A). Accordingly, in subsequent experiments, we assessed the effects of caveolin-1 protein knockdown on PDGF-BB mediated human airway myocyte responses 3 days after transient transfection with siRNA.


Figure 4
View larger version (36K):
[in this window]
[in a new window]
  		Fig. 4. Effects of small-interfering (si)RNA knockdown of the primary caveolae protein caveolin-1 on basal and PDGF-induced p42/p44 MAP kinase activation. Cells were transfected under similar conditions with either control (nonsilencing) siRNA or siRNA directed against caveolin-1. Maximum reduction of caveolin-1 due to specific siRNA transfection was observed 3 days posttransfection and was maintained for 48–72 h. A: transfection efficiency was monitored by transfecting cells with a FITC-conjugated control siRNA. FITC staining was detected in virtually all cells, which are clearly distinguishable from the precipitates of FITC-siRNA/RNAifect complexes that stick to the culture dish. Shown are a differential interference contrast (DIC) microscopy image (left) and an overlay of the DIC image with FITC-siRNA staining from the same field (right). Transfection efficiency was estimated to be ≥95%. B: 3 days after siRNA transfection cultures were then stimulated with 30 ng/ml PDGF-BB for 5 min (5') or 2 h. Equal amounts of protein lysates from each culture were then subjected to Western analysis and assayed for phosphorylated p42/p44 MAP kinase. Total p42/p44 MAP kinase, PDGFR-beta, caveolin-1, and beta-actin were also assayed. Representative blots for each protein analyzed are shown; note that caveolin-1 knockdown is ~50% in the representative Western blot. C: densitometric data for comparison of total p42/p44 MAPK, PDGFR-beta, caveolin-1, and beta-actin after treatment with caveolin-1 siRNA. Data from each experiment were normalized to cultures treated with nonsilencing control siRNA. Results shown are means ± SE obtained from 4 experiments. ***P ≤ 0.001. D: densitometric data for comparison of total phospho-p42/p44 MAP kinase at basal and after PDGF exposure. Data from each experiment were normalized to maximal (30 ng/ml, 5 min) PDGF-BB induced levels of phospho-p42/p44 MAP kinase in control cultures. Results shown are means ± SE obtained from 4 experiments. ***P < 0.001. E: densitometric data, calculated by correcting the data shown in B for basal p42/p44 MAP activation, showing the magnitude of PDGF-induced phospho-p42/p44 MAP kinase for each experiment. Results shown are the means ± SE obtained from 4 experiments. ***P ≤ 0.001.

 
The results obtained after siRNA knockdown of caveolin-1 protein on PDGF-BB-induced p42/p44 MAP kinase activation mimicked the effects, although to a lesser degree than we observed for caveolae disruption with methyl-beta-cyclodextrin (Figs. 3 and 4D). Caveolin-1 knockdown was associated with a significant approximately fourfold increase in basal activation of the p42/p44 MAP kinase pathway, confirming an inhibitory role for caveolin-1. Unlike the effect of methyl-beta-cyclodextrin treatment, siRNA knockdown of caveolin-1 did not maximally induce basal p42/p44 MAP kinase; this is likely because maximum caveolin-1 protein knockdown was only ~=50% using siRNA. Conversely, PDGF-BB-inducible p42/p44 MAP kinase activation was significantly decreased concomitant with caveolin-1 protein knockdown (Fig. 4, D and E). After PDGF exposure, caveolin-1 protein knockdown resulted in ~50% less activation of p42/p44 MAP kinase from basal levels irrespective of the time point studied, demonstrating that the inhibitory role of caveolin-1 was lost with PDGF treatment and that caveolin-1 is involved in effective induction of PDGF receptor-mediated signal transduction in human airway myocytes. Collectively our studies reveal that caveolin-1 may temper the activity of the p42/p44 MAP kinase pathway in quiescent myocytes, but it permits the induction of the same pathway on exposure to PDGF.

Role of caveolin-1 in airway myocyte proliferation. PDGF-BB is recognized as a potent mitogen for airway myocytes, and the p42/p44 MAP kinase pathway plays a key role as a positive regulator of myocyte proliferation (25, 37). Therefore, we next investigated whether the effects of caveolin-1 on p42/p44 MAP kinase signaling were also associated with effects on airway smooth muscle proliferation. For hTERT-immortalized cells, the Alamar blue assay correlates well with manual cell counting to assess proliferative responses (Fig. 5A). Four days of PDGF-BB exposure profoundly induced proliferation with an estimated EC50 of 7.3 ± 1.3 ng/ml and with a maximum response at the highest concentration tested (30 ng/ml) (Fig. 5B). Note that this maximum response did not reach a plateau, which may result in slight overestimation of the sensitivity to PDGF-BB. Nevertheless, the estimated sensitivity of hTERT immortalized to PDGF-BB is very similar to that observed by other investigators using primary cultured human airway smooth muscle cells (e.g.. EC50 of 5.9 ± 1.6 ng/ml) (22). This suggests that the molecular systems associated with PDGF receptor-mediated signaling and cell responses are effectively unchanged in hTERT human airway smooth muscle cell lines. Furthermore, in line with low-passage-number primary cultured airway myocytes, hTERT human airway myocytes retain capacity to express smMHC, a stringent contractile smooth muscle-specific protein marker, in serum-deficient conditions (Figs. 1 and 6).


Figure 6
View larger version (16K):
[in this window]
[in a new window]
  		Fig. 6. Expression of caveolin-1 and smMHC in serum-fed proliferating and quiescent, 3-day (3d) and 7-day (7d) serum-deprived hTERT human airway smooth muscle cell cultures. Total protein lysates were prepared from proliferating serum-fed, subconfluent cell cultures and from quiescent confluent cultures that had been maintained in serum-free culture media containing insulin for 3 or 7 days to induce phenotype maturation to a contractile phenotype. The abundance of caveolin-1 and sm-MHC protein was then measured by Western blot analysis and densitometry. A: representative immunoblots showing relative protein expression are shown. For all lanes, beta-actin was measured to confirm equal loading. B: densitometry analysis of Western blots. Band intensity for each protein was normalized to its abundance in quiescent, serum-deprived conditions. Results shown are means ± SE obtained from 4 experiments. *P < 0.05.

 
To determine the role of caveolin-1 in myocyte proliferation, cells were transfected with either a caveolin-1 specific or a nonsilencing control siRNA. Cells were serum deprived for 3 days during the transfection period, and 4 days thereafter airway smooth muscle cell number was estimated by Alamar Blue assay (Fig. 5, C and D). Cultures treated with PDGF-BB (30 ng/ml) for 4 days were compared with cultures maintained in serum- and growth factor-deficient media after transfection. Transfection with caveolin-1 siRNA had no acute effect on total cell number, because similar values for control and caveolin-1 siRNA were measured immediately after the transfection procedure (Fig. 5C). Conversely myocytes transfected with caveolin-1 siRNA and subsequently maintained in growth factor-deficient media for 4 days exhibited an increase in cell number that was of equal magnitude to that induced by PDGF-BB in cells transfected with control siRNA (~25%; Fig. 5D). Despite the induction of proliferation of myocytes in mitogen-free conditions, knockdown of caveolin-1 did not further induce human airway myocyte proliferation by PDGF-BB.

To test the functional involvement of p42/p44 MAP kinase activation in the cell proliferation induced by caveolin-1 specific siRNA, the MEK inhibitor U-0126 (3 µM) was applied during transfection and thereafter. Whereas caveolin-1 siRNA alone caused an increase in starting cell number (Fig. 5C), this was inhibited, even reversed to 35 ± 5% of starting cell number, by MEK inhibition. This response was similar to that measured in cultures treated with control siRNA and U-0126 (44 ± 9% of starting cell number; Fig. 5E). This suggests that p42/p44 MAP kinase is required for siRNA knockdown effects on cell proliferation.

Association of endogenous caveolin-1 abundance with airway smooth muscle phenotype. Airway smooth muscle cells can exist in mature (contractile) and immature (proliferative) phenotypes (14, 17, 20, 34). Contractile phenotype myocytes are nonproliferative and express abundant smooth muscle-specific contractile proteins, whereas immature phenotype myocytes are highly proliferative and have reduced contractile protein expression. Because our data suggest that caveolin-1 expression may regulate the proliferative capacity of human airway smooth muscle, we measured the abundance of endogenous caveolin-1 in myocytes cultured in condition to induce contractile or proliferative phenotypes. As our laboratory has described, cells were induced to a contractile phenotype during prolonged (3 and 7 days) maintenance of confluent cultures in insulin-supplemented, serum-free media, whereas myocytes of a proliferative phenotype were studied using subconfluent, serum-fed conditions (15, 18, 31). As expected, sm-MHC expression was almost five times greater in mature, quiescent airway smooth muscle cells. Interestingly, in the same cell cultures caveolin-1 protein abundance progressively increased with duration of serum deprivation and was also approximately double that we observed in proliferating myocyte cultures (Fig. 6). These data reveal that the abundance of endogenous caveolin-1 protein is variable in a phenotype and functionally dependent manner. Moreover, these data are consistent with our siRNA studies that reveal caveolin-1-deficient cells exhibit a more proliferative phenotype.

Effects of PDGF on caveolin-1 phosphorylation and association of caveolin-1 with PDGFR-beta. Because our data indicate that caveolin-1 modulates p42/p44 MAP kinase, we completed studies to investigate the temporal association between caveolin-1 and p42/p44 MAP kinase phosphorylation in response to PDGF. Moreover, we investigated the temporal association of caveolin-1 binding with PDGFR-beta. Phosphorylation of caveolin-1 at the Tyr14 position has been demonstrated after growth factor treatment in NIH3T3 cells (28), and this is associated with promitotic signaling and proliferation. Therefore, we first monitored basal and time-dependent Tyr14 phosphorylation of caveolin-1 induced by PDGF-BB (30 ng/ml) (Fig. 7). Modest caveolin-1 phosphorylation was evident under basal conditions; however, within 5 min of PDGF addition, an increase in Tyr14 phosphorylation was evident, and it reached peak levels by 15 min. The rate and magnitude of caveolin-1 phosphorylation were similar to that we observed for p42/p44 MAP kinase activation after PDGF treatment. We next investigated whether a direct association existed between caveolin-1 and PDGFR-beta in human airway myocytes and whether this might be modulated by addition of agonist. Under basal conditions where caveolin-1 phosphorylation is minimal, PDGFR-beta was abundant in caveolin-1 immunoprecipitates, suggesting a significant interaction between the proteins (Fig. 8). Of note, within 5 min of exposure to PDGF-BB the dissociation of most PDGFR-beta from caveolin-1 was evident. The temporal pattern for dissociation of PDGFR-beta from caveolin-1 is similar to that we observed for PDGF-BB-induced phosphorylation of caveolin-1 and of p42/p44 MAP kinase.


Figure 7
View larger version (21K):
[in this window]
[in a new window]
  		Fig. 7. Effects of PDGF-BB on caveolin-1 and p42/p44 MAP kinase phosphorylation. Subconfluent cell cultures were equilibrated in serum-free media for 3 days, then were stimulated with 30 ng/ml PDGF-BB, and protein lysates were collected at specific time points up to 120 min, as indicated. Equal protein was loaded and then subjected to Western blot analysis and densitometry to assay Thr202/Tyr204 phosphorylated (phospho-) p42/p44 MAP kinase and Tyr14 phosphorylated (phospho-) caveolin-1. Total p42/p44 MAP kinase and caveolin-1 were also assayed to ensure equal loading. A: representative immunoblots demonstrating temporal response of hTERT human airway myocytes to PDGF-BB exposure. B: densitometry assay of phospho-p42/p44 MAP kinase and phospho-caveolin-1 after PDGF-BB exposure. Data are normalized for each protein to their corresponding maximum values for both caveolin-1 and p42/p44 MAP kinase. Results shown are means ± SE obtained from 4 experiments.

 

Figure 8
View larger version (19K):
[in this window]
[in a new window]
  		Fig. 8. PDGF-BB exposure leads to the disassociation of PDGFR-beta from caveolin-1. Subconfluent cell cultures were equilibrated in serum-free media for 3 days, then were stimulated with 30 ng/ml PDGF-BB, and protein lysates were collected at different times for up to 120 min, as indicated. From equal amounts of total protein from each lysate, caveolin-1 was immunoprecipitated using protein-specific polyclonal rabbit IgG. Thereafter, the immunoprecipitates (IP) were assayed for PDGFR-beta and caveolin-1 by Western analysis using protein-specific primary antibodies. A: representative immunoblots (IB) from 1 experiment showing the temporal effect myocyte exposure to PDGF-BB on the association of PDGFR-beta with caveolin-1. B: densitometry assay showing the abundance of PDGFR-beta that was immunoprecipitated in association with caveolin-1 and the temporal effect myocyte exposure to PDGF-BB. Results shown are means ± SE obtained from 3 experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
The concept that signaling molecules are compartmentalized in cells to facilitate and integrate effective and timely modulation of critical cell functions in response to multiple stimuli has moved to the forefront of cell biology research, and caveolae appear to play a role in this regard in different cell types, including smooth muscle cells (2, 38, 44). Caveolae are abundant in the lung and on airway smooth muscle cells; however, to date, the only studies available have focused on their potential role in Ca2+ handling (8, 27). The present study significantly extends understanding of the role of caveolae and caveolin-1 in airway smooth muscle because it is the first to describe their role in constitutive and PDGF-induced p42/p44 MAP kinase signaling and airway myocyte proliferation. Moreover, our studies provide new insight indicating a requirement for caveolin-1 in both suppressing constitutive p42/p44 MAP kinase signaling in quiescent cells and for permitting induction of p42/p44 MAP kinase signaling in myocytes stimulated with the potent mitogen, PDGF-BB.

Our data reveal for the first time that caveolae and caveolin-1 repress p42/p44 MAP kinase activity in quiescent airway smooth muscle cells. Disruption of caveolae using methyl-beta-cyclodextrin and knockdown of caveolin-1 using siRNA resulted in activation of basal p42/p44 MAP kinase signaling; additionally, caveolin-1 knockdown induced airway smooth muscle proliferation even in the absence of exogenous mitogens. These observations are highly consistent with reports indicating that embryonic fibroblasts, vascular smooth muscle cells, and alveolar epithelial cells from caveolin-1 null mice exhibit hyperproliferative properties (12, 42). Furthermore, cholesterol depletion has also been reported to hyperactivate the p42/p44 MAP kinase cascade in cultured fibroblasts (11). We also examined endogenous expression of caveolin-1 and found it to correlate with the functional and phenotypic status of airway myocytes. The highest abundance was observed in quiescent, phenotypically contractile myocytes, which expressed more than twofold more caveolin-1 than serum-fed proliferating cells. These results are similar to recent data from studies with primary cultured vascular smooth muscle cells, where caveolin-1 abundance decreased substantially in proliferating myocytes stimulated with PDGF (39). Other studies have shown an antiproliferative role for caveolin-1 overexpressed in mesangial cells or NIH3T3 fibroblasts that involves, respectively, either the suppression of growth factor-induced p42/p44 MAP kinase activity or the induction of p53 and p21Waf1/Cip1, which leads to cell cycle arrest (10, 12). Similar antiproliferative effects of overexpressed caveolin-1 were seen in vascular smooth muscle cells in a more recent study, although in these cells, the inhibitory effects of caveolin-1 were mediated by inhibition of cyclin D1 accumulation (39). Furthermore, caveolin-1 (39) and caveolae (48) expression were previously found to be dependent on the proliferating state of vascular smooth muscle cells, with highest expression in quiescent cells. Our results therefore support an antimitogenic role for caveolin-1, and demonstrate that endogenous levels of caveolin-1 are sufficient to manifest antimitogenic effects in airway smooth muscle cells.

Our studies further demonstrate that PDGFR-beta, which is the primary PDGF receptor isoform for PDGF-BB in airway smooth muscle (22), is almost exclusively localized to caveolae in association with caveolin-1 in quiescent cells. This is consistent with studies in normal human fibroblasts showing that the constituents of the proximal PDGF receptor signaling cassette responsible for p42/p44 MAP kinase activation, including PDGFR-beta, Src, Shc, Grb2, and Ras, are localized to caveolae (29, 30). We also demonstrated that the majority of p42/p44 MAP kinase is not caveolae associated; this finding is compatible with other evidence obtained using confocal microscopy indicating a cytoplasmic and/or nuclear distribution of the enzyme in airway smooth muscle cells (5). This suggests that more distal components of Ras signaling cascades at the level of p42/p44 MAP kinase may be spatially dissociated from caveolae. Because our data clearly demonstrate a requirement for caveolin-1 in attenuating p42/p44 MAP kinase activity in quiescent cells and for permitting the enzyme’s activation in PDGF-stimulated cells, it seems plausible that caveolin-1 is an essential component of upstream, membrane-associated components of PDGFR-beta signaling cascades in human airway myocytes.

PDGF-BB readily activated the p42/p44 MAP kinase pathway in human airway myocytes. Notably, as evident from our studies using siRNA, caveolin-1 did not attenuate the capacity for PDGF-BB to induce rapid phosphorylation of p42/p44 MAP kinase. Rather, PDGF-induced increases in p42/p44 MAP kinase phosphorylation was ~50% less; this demonstrates that the inhibitory role of caveolin-1 in quiescent cells is attenuated after PDGF exposure and that caveolin-1 might mediate effective induction of PDGF receptor signaling. Furthermore, we demonstrate that the reduced ability for further activation of p42/p44 MAP kinase in caveolin-1 knockdown cells translates into more profound effects on airway smooth muscle proliferation, because after siRNA treatment PDGF-BB did not promote myocyte proliferation above basal levels. This suggests that functional properties of caveolin-1, perhaps as an anchor for receptors and signaling proteins via its 21-amino acid NH2-terminal caveolin scaffolding domain, are essential for caveolae regulation of PDGFR-beta-mediated signaling in human airway smooth muscle cells. This fits with emerging paradigms holding caveolins as core scaffolding and signal-modifying proteins in so-called signalosomes that effect and fine tune receptor-mediated signaling for a broad range of cellular responses (36, 46). Therefore, in our studies with human airway myocytes, knockdown of caveolin-1 might facilitate the disorganization of proximal PDGFR-beta-associated signaling effectors and interfere with mitogen-mediated signal transduction that leads to activation of more distal signaling proteins.

It is of considerable interest to understand how the ability for caveolin-1 to serve as an antimitogenic effector in quiescent cells is regulated by PDGF. In NIH3T3 fibroblasts, Tyr14 phosphorylation of caveolin-1 is induced by growth factors, and results in the recruitment of the adaptor protein Grb7 to caveolin-1 with subsequent signaling that promotes DNA synthesis (28). In our study, we also demonstrated rapid and sustained caveolin-1 phosphorylation at Tyr14 with PDGF-BB addition. We further observed that PDGFR-beta was closely associated with caveolin-1 but only in quiescent cells; this finding is consistent with previous reports of caveolin-1 acting as an inhibitor of PDGF-beta (53). With myocyte stimulation with PDGF-BB, a dramatic rapid and sustained reduction in caveolin-1/PDGFR-beta association was evident, which led to a temporally similar activation profile for p42/p44 MAP kinase and to myocyte proliferation. To our knowledge, no prior studies have demonstrated a dynamic association of caveolin-1 with PDGFR-beta that is dependent on receptor-agonist binding. There are, however, other reports that support the idea for a dynamic relationship between caveolin-1 and growth factor receptors that is dependent on the activation state of the receptor. For example, angiotensin II causes a decrease in caveolin-1 binding with epidermal growth factor receptor (EGFR), resulting in EGFR transactivation (49). Furthermore, in human glioblastoma cells, inactive but not phosphorylated EGFR associates with caveolin-1 peptides that harbor the caveolin scaffolding domain (1). Therefore, caveolin-1 appears to be a central component in immediate signal transduction events associated with growth factor receptors. Moreover, the phosphorylation of caveolin-1 may be a key step in initiating signal transduction cascades mediated by PDGFR-beta in human airway smooth muscle cells.

Although the results of the present study point to an unambiguous functional interaction of caveolin-1 and caveolae with PDGFR-beta signaling, we cannot rule out the additional involvement of caveolin-2 in our siRNA studies. Although to a much lesser degree that caveolin-1, caveolin-2 is expressed by smooth muscle cells (6). Of note, caveolin-2 abundance appears to be decreased by experimental approaches (e.g., siRNA knockdown, knockout mice) that ablate caveolin-1 expression (4, 42). Moreover, caveolin-2 knockout mice show a similar hypercellular lung parenchymal phenotype as caveolin-1 knockout mice (42, 43). Thus it is possible that the effects we observe of caveolin-1 siRNA treatment on PDGF signal transduction and proliferation could also involve effects due to caveolin-2 knockdown. Because in airway smooth muscle the primary caveolae protein expressed is caveolin-1 (6), it was beyond the scope of the present study to also investigate whether caveolin-2 regulates PDGF signaling and myocyte proliferation. Nonetheless, our present experiments provide strong rationale for future studies to investigate the specific role of caveolin-2 in growth factor-induced airway smooth muscle proliferation.

A novel aspect of our studies is that we employed newly developed human bronchial smooth muscle cell lines prepared using a retroviral vector to facilitate stable integration and expression of the coding sequence for hTERT. Because hTERT does not directly modulate signal transduction pathways that control cell proliferation, overexpression of hTERT has been used as an effective strategy for immortalization of a number of different cell types, including endothelial cells, fibroblasts, and smooth muscle cells, that retain the capacity to exhibit key characteristics of the mature cell phenotype (3, 7, 32, 33, 52, 54). The overexpression of hTERT, a subunit of a telomerase complex that maintains telomere length after DNA replication and cell division, effectively confers resistance to replication senescence. The cell lines used in our studies have been cultured up to 60 passages without evidence of a loss in proliferative capacity, whereas matched primary cultures typically lose replication capacity around passage 23 (13). Unlike primary cell lines, the hTERT human airway myocytes appear to indefinitely retain the capacity for reexpression of a contractile phenotype; even after passage 15, prolonged serum deprivation induced significant accumulation of protein markers of the mature smooth muscle cell phenotype (Figs. 1 and 6) (17, 18, 20). Furthermore, in a manner that closely mimics primary cultured vascular smooth muscle cells (39), we found caveolin-1 expression to be significantly reduced when myocytes are induced to a proliferative state by mitogen exposure. Perhaps most importantly for our studies, the expression of hTERT in airway myocytes had no effect on the sensitivity of myocytes for PDGF-BB induced proliferation, because the EC50 value we measured is very similar to published reports using low-passage-number, primary cultured human airway smooth muscle cells (22). Collectively, these observations indicate that hTERT-immortalized human bronchial smooth muscle cells are well suited for investigating fundamental molecular mechanisms associated with caveolae and caveolin-1 in myocyte biology.

In light of the inhibitory role caveolin-1 appears to have on constitutive p42/p44 MAP kinase activation and proliferation, it will be interesting to determine whether its expression and phosphorylation state are altered in chronic airways diseases. Recent evidence reveals that caveolin-1 abundance is significantly decreased in proliferating vascular smooth muscle cells present in human atheromatous plaques, a situation characterized by pronounced myocyte proliferation (45). If caveolin-1 expression is similarly depressed in inflammatory airways disease, this could contribute to the increase in muscle mass that characterizes airway remodeling. Interestingly, primary cultured airway smooth muscle cells isolated from human asthmatic subjects exhibit an intrinsic hyperproliferative character; however, to our knowledge, there have been no studies investigating caveolin-1 expression in these cells (24).

In conclusion, the results described in this study indicate a significant role for caveolin-1 in regulating basal and PDGF-induced p42/p44 MAP kinase activation and airway smooth muscle proliferation. Caveolin-1 has a strong antimitogenic role, because it appears to be required for the quenching of constitutive activity of p42/p44 MAP kinase in quiescent myocytes. Indeed, we found that siRNA knockdown of caveolin-1 was sufficient to promote p42/p44 MAP kinase activation and airway smooth muscle proliferation in the absence of exogenous mitogen exposure. This antimitogenic role is consistent with the relatively high abundance of caveolin-1 protein we observed in mature, contractile airway smooth muscle cells. Conversely, after PDGF exposure, the antimitogenic role of caveolin-1 switches to permit p42/p44 MAP kinase signaling and proliferation. By organizing PDGFR-beta and its proximal signaling effectors, caveolae and caveolin-1 may even support molecular interactions that are required for PDGF-induced p42/p44 MAP kinase activation. The precise molecular mechanism that releases caveolin-1 from an antimitogenic role in mitogen-stimulated myocytes are not clear; however, our studies offer some novel insights. PDGF-BB exposure triggered rapid and sustained phosphorylation of caveolin at Tyr14 and the dissociation of PDGFR-beta, which was otherwise tightly associated with caveolin-1 in quiescent cells. Collectively, these results suggest a complex role for caveolae and caveolin-1 in regulating basal and growth factor-induced signaling and proliferation of airway smooth muscle.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by grants from the Sick Kids Foundation/Institute of Human Development, Child and Youth Health (no. XG05-011), Canadian Institutes of Health Research (CIHR), and the Manitoba Institute of Child Health. R. Gosens received support from the National Training Program in Allergy and Asthma and is currently the recipient of a Marie Curie Outgoing International Fellowship (no. 008823). A. J. Halayko is supported by a CIHR New Investigator Award.


   FOOTNOTES
 

Address for reprint requests and other correspondence: R. Gosens, Dept. of Physiology, Univ. of Manitoba, 715 McDermot Ave., Rm. 547, John Buhler Research Centre, Winnipeg, Manitoba, Canada R3E 3P4 (e-mail: rgosens{at}mich.ca)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, and Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene 23: 6967–6979, 2004.[CrossRef][Web of Science][Medline]
  2. Bergdahl A and Sward K. Caveolae-associated signalling in smooth muscle. Can J Physiol Pharmacol 82: 289–299, 2004.[CrossRef][Web of Science][Medline]
  3. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, and Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352, 1998.[Abstract/Free Full Text]
  4. Cho WJ and Daniel EE. Colocalization between caveolin isoforms in the intestinal smooth muscle and interstitial cells of Cajal of the Cav1(+/+) and Cav1(–/–) mouse. Histochem Cell Biol 1–8, 2005.
  5. Citro S, Ravasi S, Rovati GE, and Capra V. Thromboxane prostanoid receptor signals through Gi protein to rapidly activate extracellular signal-regulated kinase in human airways. Am J Respir Cell Mol Biol 32: 326–333, 2005.[Abstract/Free Full Text]
  6. Cohen AW, Hnasko R, Schubert W, and Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341–1379, 2004.[Abstract/Free Full Text]
  7. Condon J, Yin S, Mayhew B, Word RA, Wright WE, Shay JW, and Rainey WE. Telomerase immortalization of human myometrial cells. Biol Reprod 67: 506–514, 2002.[Abstract/Free Full Text]
  8. Darby PJ, Kwan CY, and Daniel EE. Caveolae from canine airway smooth muscle contain the necessary components for a role in Ca2+ handling. Am J Physiol Lung Cell Mol Physiol 279: L1226–L1235, 2000.[Abstract/Free Full Text]
  9. Foster LJ, De Hoog CL, and Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci USA 100: 5813–5818, 2003.[Abstract/Free Full Text]
  10. Fujita Y, Maruyama S, Kogo H, Matsuo S, and Fujimoto T. Caveolin-1 in mesangial cells suppresses MAP kinase activation and cell proliferation induced by bFGF and PDGF. Kidney Int 66: 1794–1804, 2004.[CrossRef][Web of Science][Medline]
  11. Furuchi T and Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem 273: 21099–21104, 1998.[Abstract/Free Full Text]
  12. Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG, and Lisanti MP. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell 12: 2229–2244, 2001.[Abstract/Free Full Text]
  13. Gerthoffer WT, Pari GS, and Wysolmerski RB. Immortalized human airway smooth muscle cells with a contractile phenotype (Abstract). Am J Respir Crit Care Med 169: A188, 2004.
  14. Gosens R, Meurs H, Bromhaar MM, McKay S, Nelemans SA, and Zaagsma J. Functional characterization of serum- and growth factor-induced phenotypic changes in intact bovine tracheal smooth muscle. Br J Pharmacol 137: 459–466, 2002.[CrossRef][Web of Science][Medline]
  15. Gosens R, Nelemans SA, Hiemstra M, Grootte Bromhaar MM, Meurs H, and Zaagsma J. Insulin induces a hypercontractile airway smooth muscle phenotype. Eur J Pharmacol 481: 125–131, 2003.[CrossRef][Web of Science][Medline]
  16. Hailstones D, Sleer LS, Parton RG, and Stanley KK. Regulation of caveolin and caveolae by cholesterol in MDCK cells. J Lipid Res 39: 369–379, 1998.[Abstract/Free Full Text]
  17. Halayko AJ, Salari H, Ma X, and Stephens NL. Markers of airway smooth muscle cell phenotype. Am J Physiol Lung Cell Mol Physiol 270: L1040–L1051, 1996.[Abstract/Free Full Text]
  18. Halayko AJ, Camoretti-Mercado B, Forsythe SM, Vieira JE, Mitchell RW, Wylam ME, Hershenson MB, and Solway J. Divergent differentiation paths in airway smooth muscle culture: induction of functionally contractile myocytes. Am J Physiol Lung Cell Mol Physiol 276: L197–L206, 1999.[Abstract/Free Full Text]
  19. Halayko AJ, Kartha S, Stelmack GL, McConville J, Tam J, Camoretti-Mercado B, Forsythe SM, Hershenson MB, and Solway J. Phophatidylinositol-3 kinase/mammalian target of rapamycin/p70S6K regulates contractile protein accumulation in airway myocyte differentiation. Am J Respir Cell Mol Biol 31: 266–275, 2004.[Abstract/Free Full Text]
  20. Halayko AJ, Stelmack GL, Yamasaki A, McNeill K, Unruh H, and Rector E. Distribution of phenotypically disparate myocyte subpopulations in airway smooth muscle. Can J Physiol Pharmacol 83: 104–116, 2005.[CrossRef][Web of Science][Medline]
  21. Hays SR, Ferrando RE, Carter R, Wong HH, and Woodruff PG. Structural changes to airway smooth muscle in cystic fibrosis. Thorax 60: 226–228, 2005.[Abstract/Free Full Text]
  22. Hirst SJ, Barnes PJ, and Twort CH. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 270: L415–L428, 1996.[Abstract/Free Full Text]
  23. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164: S28–S38, 2001.[Abstract/Free Full Text]
  24. Johnson PR, Roth M, Tamm M, Hughes M, Ge Q, King G, Burgess JK, and Black JL. Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med 164: 474–477, 2001.[Abstract/Free Full Text]
  25. Kelleher MD, Abe MK, Chao TS, Jain M, Green JM, Solway J, Rosner MR, and Hershenson MB. Role of MAP kinase activation in bovine tracheal smooth muscle mitogenesis. Am J Physiol Lung Cell Mol Physiol 268: L894–L901, 1995.[Abstract/Free Full Text]
  26. Kilsdonk EP, Yancey PG, Stoudt GW, Bangerter FW, Johnson WJ, Phillips MC, and Rothblat GH. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 270: 17250–17256, 1995.[Abstract/Free Full Text]
  27. Kuo KH, Herrera AM, and Seow CY. Ultrastructure of airway smooth muscle. Respir Physiol Neurobiol 137: 197–208, 2003.[CrossRef][Web of Science][Medline]
  28. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE, and Lisanti MP. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750–1775, 2000.[Abstract/Free Full Text]
  29. Liu P, Ying Y, Ko YG, and Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 271: 10299–10303, 1996.[Abstract/Free Full Text]
  30. Liu P, Ying Y, and Anderson RG. Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proc Natl Acad Sci USA 94: 13666–13670, 1997.[Abstract/Free Full Text]
  31. Ma X, Wang Y, and Stephens NL. Serum deprivation induces a unique hypercontractile phenotype of cultured smooth muscle cells. Am J Physiol Cell Physiol 274: C1206–C1214, 1998.[Abstract/Free Full Text]
  32. McKee JA, Banik SS, Boyer MJ, Hamad NM, Lawson JH, Niklason LE, and Counter CM. Human arteries engineered in vitro. EMBO Rep 4: 633–638, 2003.[CrossRef][Web of Science][Medline]
  33. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, and Campana D. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120: 846–849, 2003.[CrossRef][Web of Science][Medline]
  34. Moir LM, Ward JP, and Hirst SJ. Contractility and phenotype of human bronchiole smooth muscle after prolonged fetal bovine serum exposure. Exp Lung Res 29: 339–359, 2003.[CrossRef][Web of Science][Medline]
  35. Naureckas ET, Ndukwu IM, Halayko AJ, Maxwell C, Hershenson MB, and Solway J. Bronchoalveolar lavage fluid from asthmatic subjects is mitogenic for human airway smooth muscle. Am J Respir Crit Care Med 160: 2062–2066, 1999.[Abstract/Free Full Text]
  36. Okamoto T, Schlegel A, Scherer PE, and Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273: 5419–5422, 1998.[Free Full Text]
  37. Orsini MJ, Krymskaya VP, Eszterhas AJ, Benovic JL, Panettieri RA Jr, and Penn RB. MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. Am J Physiol Lung Cell Mol Physiol 277: L479–L488, 1999.[Abstract/Free Full Text]
  38. Ostrom RS and Insel PA. The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology. Br J Pharmacol 143: 235–245, 2004.[CrossRef][Web of Science][Medline]
  39. Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, Sowa G, Gores GJ, Sessa WC, and Simari RD. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol 23: 1521–1527, 2003.[Abstract/Free Full Text]
  40. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 378: 281–292, 2004.[CrossRef][Web of Science][Medline]
  41. Rahman MS, Yang J, Shan LY, Unruh H, Yang X, Halayko AJ, and Gounni AS. IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcriptional-dependent mechanism. Clin Immunol 115: 268–276, 2005.[CrossRef][Web of Science][Medline]
  42. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, and Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 276: 38121–38138, 2001.[Abstract/Free Full Text]
  43. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H Jr,. Christ GJ, Edelmann W, and Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 22: 2329–2344, 2002.[Abstract/Free Full Text]
  44. Razani B, Woodman SE, and Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431–467, 2002.[Abstract/Free Full Text]
  45. Schwencke C, Schmeisser A, Walter C, Wachter R, Pannach S, Weck B, Braun-Dullaeus RC, Kasper M, and Strasser RH. Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res 68: 128–135, 2005.[Abstract/Free Full Text]
  46. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, and Lisanti MP. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19: 7289–7304, 1999.[Free Full Text]
  47. Stehr M, Adam RM, Khoury J, Zhuang L, Solomon KR, Peters CA, and Freeman MR. Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence on lipid rafts for cell signaling. J Urol 169: 1165–1170, 2003.[CrossRef][Web of Science][Medline]
  48. Thyberg J, Roy J, Tran PK, Blomgren K, Dumitrescu A, and Hedin U. Expression of caveolae on the surface of rat arterial smooth muscle cells is dependent on the phenotypic state of the cells. Lab Invest 77: 93–101, 1997.[Web of Science][Medline]
  49. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, and Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 276: 48269–48275, 2001.[Abstract/Free Full Text]
  50. Wang PY, Weng J, and Anderson RG. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. Science 307: 1472–1476, 2005.[Abstract/Free Full Text]
  51. Woodruff PG, Dolganov GM, Ferrando RE, Donnelly S, Hays SR, Solberg OD, Carter R, Wong HH, Cadbury PS, and Fahy JV. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 169: 1001–1006, 2004.[Abstract/Free Full Text]
  52. Xu C, Jiang J, Sottile V, McWhir J, Lebkowski J, and Carpenter MK. Immortalized fibroblast-like cells derived from human embryonic stem cells support undifferentiated cell growth. Stem Cells 22: 972–980, 2004.[CrossRef][Web of Science][Medline]
  53. Yamamoto M, Toya Y, Jensen RA, and Ishikawa Y. Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 247: 380–388, 1999.[CrossRef][Web of Science][Medline]
  54. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, Bronstein A, Chiu CP, and Herron GS. Human endothelial cell life extension by telomerase expression. J Biol Chem 274: 26141–26148, 1999.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. O. Nunes, M. Schmidt, G. Dueck, H. Baarsma, A. J. Halayko, H. A. M. Kerstjens, H. Meurs, and R. Gosens
GSK-3/{beta}-catenin signaling axis in airway smooth muscle: role in mitogenic signaling
Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1110 - L1118.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
R. B. Penn and J. L. Benovic
Regulation of Heterotrimeric G Protein Signaling in Airway Smooth Muscle
Proceedings of the ATS, January 1, 2008; 5(1): 47 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
A. J. Halayko, T. Tran, and R. Gosens
Phenotype and Functional Plasticity of Airway Smooth Muscle: Role of Caveolae and Caveolins
Proceedings of the ATS, January 1, 2008; 5(1): 80 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. Sharma, T. Tran, G. L. Stelmack, K. McNeill, R. Gosens, M. M. Mutawe, H. Unruh, W. T. Gerthoffer, and A. J. Halayko
Expression of the dystrophin-glycoprotein complex is a marker for human airway smooth muscle phenotype maturation
Am J Physiol Lung Cell Mol Physiol, January 1, 2008; 294(1): L57 - L68.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. Tran, K. Ens-Blackie, E. S. Rector, G. L. Stelmack, K. D. McNeill, G. Tarone, W. T. Gerthoffer, H. Unruh, and A. J. Halayko
Laminin-Binding Integrin {alpha}7 Is Required for Contractile Phenotype Expression by Human Airway Myocytes
Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 668 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. Gosens, G. L. Stelmack, G. Dueck, M. M. Mutawe, M. Hinton, K. D. McNeill, A. Paulson, S. Dakshinamurti, W. T. Gerthoffer, J. A. Thliveris, et al.
Caveolae facilitate muscarinic receptor-mediated intracellular Ca2+ mobilization and contraction in airway smooth muscle
Am J Physiol Lung Cell Mol Physiol, December 1, 2007; 293(6): L1406 - L1418.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. S. Prakash, M. A. Thompson, B. Vaa, I. Matabdin, T. E. Peterson, T. He, and C. M. Pabelick
Caveolins and intracellular calcium regulation in human airway smooth muscle
Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1118 - L1126.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. Gosens, G. Dueck, E. Rector, R. O. Nunes, W. T. Gerthoffer, H. Unruh, J. Zaagsma, H. Meurs, and A. J. Halayko
Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation
Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1348 - L1358.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. Albinsson, Y. Shakirova, A. Rippe, M. Baumgarten, B.-I. Rosengren, C. Rippe, R. Hallmann, P. Hellstrand, B. Rippe, and K. Sward
Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1222 - R1231.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. Gosens, G. Dueck, W. T. Gerthoffer, H. Unruh, J. Zaagsma, H. Meurs, and A. J. Halayko
p42/p44 MAP kinase activation is localized to caveolae-free membrane domains in airway smooth muscle
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1163 - L1172.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/3/L523    most recent
00013.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gosens, R.
Right arrow Articles by Halayko, A. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gosens, R.
Right arrow Articles by Halayko, A. J

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.